You are here: Home: Audio Program Guide: BCU 5 | 2008 Audio: BCU 5 | 2008
 
  Go to interview with Nancy E Davidson, MD
Go to interview with Professor John Crown, MD
Go to interview with Kathy D Miller, MD
Go to interview with Peter M Ravdin, MD, PhD
Go to interview with Norman Wolmark, MD
Go to interview with Joyce O’Shaughnessy, MD
Go to Interview with Eric P Winer, MD
 


To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Nancy E Davidson, MD
Breast Cancer Research
Professor of Oncology
Director of the Breast Cancer Program
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins
Baltimore, Maryland
  
  Click here to download the entire interview  
Track 1 ABCSG-12: Adjuvant ovarian suppression and tamoxifen or anastrozole, with or without zoledronic acid, in premenopausal women with ER/PR-positive breast cancer (BC)
Track 2 SOFT and TEXT: Ovarian suppression combined with endocrine therapy for premenopausal patients with ER/PR-positive BC
Track 3 ABCSG-12: Cancer recurrence and zoledronic acid
Track 4 Ongoing clinical trials of adjuvant bisphosphonates
Track 5 Prospective study of adjuvant anastrozole and gene promoter methylation in the contralateral breast of
women at high risk
Track 6 Clinical trials of the HDAC inhibitor vorinostat

Track 7 Long-term therapeutic strategies for ER/PR-positive BC
Track 8 ATLAS and aTTom trials of adjuvant tamoxifen beyond five years
Track 9 Adjuvant endocrine therapy for women with chemotherapy-induced amenorrhea
Track 10 Pathophysiology of aromatase inhibitor-associated arthralgias
Track 11 Novel biologic strategies simultaneously targeting multiple pathways
Track 12 Anti-EGFR tyrosine kinase inhibitors (TKIs) combined with endocrine therapy
     
Professor John Crown, MD
Consultant Medical Oncologist
St Vincent’s University Hospital and
Thomas Baldwin Chair in
Cancer Research
Dublin City University
Dublin, Ireland
  
  Click here to download the entire interview  
Track 1 tAnGo: A Phase III trial of adjuvant EC paclitaxel with or without gemcitabine
Track 2 Use of adjuvant docetaxel/cyclophosphamide (TC) for patients with HER2-negative BC
Track 3 Weighing the risks and benefits of adjuvant anthracyclines
Track 4 Clinical trials of adjuvant docetaxel/cyclophosphamide with bevacizumab for patients with HER2-negative BC
Track 5 Use of adjuvant docetaxel/carboplatin/trastuzumab (TCH) for patients with HER2-positive BC
Track 6 Adjuvant chemotherapy/trastuzumab for small (<1-cm), node-negative, HER2-positive tumors

Track 7 Trastuzumab/chemotherapy regimens and risk of cardiotoxicity
Track 8 Dual action of lapatinib, targeting HER2 and EGF receptors
Track 9 Management of lapatinib-induced toxicities
Track 10 Clinical trials evaluating lapatinib-based combination therapies
Track 11 ALTTO and BETH: Clinical trials of adjuvant anti-HER2 therapy
Track 12 Rationale for the TCH-based regimen in the BETH trial

Track 13 AVADO results: First-line docetaxel with or without bevacizumab for locally recurrent or metastatic breast cancer (mBC)
Track 14 BEATRICE: Adjuvant chemotherapy with or without bevacizumab for triple-negative BC
Track 15 Importance of patient selection in the development of molecularly targeted therapies
Track 16 Perspective on ABCSG-12
Track 17 Clinical impact of the zoledronic acid data from ABCSG-12
     
Kathy D Miller, MD
Sheila D Ward Scholar of Medicine
Associate Professor of Medicine
Indiana University Simon Cancer Center
Indianapolis, Indiana
  
  Click here to download the entire interview  
Track 1 Bevacizumab-related toxicities and its incorporation into adjuvant clinical trials
Track 2 ECOG-E5103: AC weekly paclitaxel with or without bevacizumab in early BC
Track 3 Potential effects of bevacizumab in the adjuvant setting
Track 4 US Oncology TC-TAC-TC/bevacizumab adjuvant trial in HER2-negative early BC
Track 5 AVADO: Docetaxel with or without bevacizumab for locally recurrent or mBC
Track 6 Accrual to E5103

Track 7 Need for continued evaluation of the role for adjuvant anthracyclines
Track 8 BETH trial: Adjuvant chemotherapy and trastuzumab with or without bevacizumab in HER2-positive BC
Track 9 Research on trastuzumab/bevacizumab for patients with mBC
Track 10 Novel anti-HER2 therapeutics in BC: pertuzumab, T-DM1
Track 11 Clinical trial results with EGFR TKIs and hormonal therapy in mBC

     
Peter M Ravdin, MD, PhD
Research Professor of Biostatistics
The University of Texas
MD Anderson Cancer Center
Houston, Texas		  
  Click here to download the entire interview  
Track 1 Implications of recent increased incidence of BC due to earlier detection
Track 2 Use of paraffin-embedded tissue with the Oncotype DX® assay versus frozen tissue with the MammaPrint® assay
Track 3 MINDACT: Comparison of MammaPrint to Adjuvant! in selecting patients with node-negative BC for adjuvant chemotherapy
Track 4 Use of standard pathology criteria in combination with the Oncotype DX assay in clinical decision-making
Track 5 Utility of Oncotype DX in predicting benefit from chemotherapy for patients with node-negative and node-positive BC
Track 6 ASCO Tumor Marker Committee and NCCN recommendations for use of Oncotype DX

Track 7 Risk predictors for BC based on biological subtypes
Track 8 Quantitative assessment of ER and HER2 with the Oncotype DX assay
Track 9 Viewpoint on the ABCSG-12 zoledronic acid data
Track 10 Translation of treatment benefits from the metastatic to the adjuvant setting

Track 11 Incorporation of adjuvant therapy with trastuzumab into Adjuvant! Online
     
Norman Wolmark, MD
Chairman, National Surgical Adjuvant
Breast and Bowel Project
Chairman, Department
of Human Oncology
Allegheny General Hospital
Pittsburgh, Pennsylvania
Professor of Human Oncology
Drexel University College of Medicine
Philadelphia, Pennsylvania		  
  Click here to download the entire interview  
Track 1 BETH trial: Adjuvant chemotherapy/trastuzumab with or without bevacizumab in HER2-positive BC
Track 2 Role of adjuvant anthracycline-based therapy in BC
Track 3 NSABP/US Oncology partnership in the adjuvant TC-TAC-TC/bevacizumab study
Track 4 Does adjuvant trastuzumab provide benefit to patients with “HER2-low” BC?
Track 5 Perspective on the ALTTO trial evaluating adjuvant trastuzumab with lapatinib
Track 6 NSABP-B-45: Sunitinib for residual BC after neoadjuvant chemotherapy

     
Joyce O’Shaughnessy, MD
Co-Director
Breast Cancer Research Program
Baylor-Charles A Sammons
Cancer Center
Texas Oncology, PA
US Oncology
Dallas, Texas
  
  Click here to download the entire interview  
Track 1 A “Manhattan Project” for understanding the molecular circuitry of cancer
Track 2 US Oncology TC-TAC-TC/bevacizumab adjuvant trial
Track 3 US Oncology neoadjuvant studies evaluating the impact of anti-HER2 therapy on stem cells
Track 4 Dose reductions and patient education in managing side effects of paclitaxel/lapatinib
Track 5 Lapatinib with or without trastuzumab in heavily pretreated mBC progressing on trastuzumab
Track 6 Capecitabine/lapatinib in the treatment of brain metastases from HER2-positive BC

Track 7 Dramatic reduction of liver metastases in a heavily pretreated woman receiving lapatinib/trastuzumab
Track 8 Clinical use of chemotherapy with lapatinib/trastuzumab in HER2-positive mBC
Track 9 Rationale for combining bevacizumab with a nonanthracycline-containing regimen (TC) in the US Oncology adjuvant trial
Track 10 Use of anthracycline-containing adjuvant regimens in node-positive or high-risk, node-negative BC
Track 11 Selection of patients for treatment with adjuvant TC chemotherapy
Track 12 Applicability of the Oncotype DX assay for treatment decision-making in node-positive BC

Track 13 Quantitative assessment of ER and PR with the Oncotype DX assay
Track 14 Clinical management of bevacizumab- and trastuzumab-associated hypertension in the adjuvant setting
     
Eric P Winer, MD
Thompson Investigator
in Breast Cancer Research
Director, Breast Oncology Center
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
  
  Click here to download the entire interview  
Track 1 Evaluating biological subtypes in BC clinical trials
Track 2 Anticipated translation of clinical trials targeting biologic subtypes into reductions in breast cancer mortality
Track 3 Controversy regarding the benefit of adjuvant trastuzumab in patients with “HER2-low” BC
Track 4 Proposal for an adjuvant clinical trial to evaluate “HER2-low” BC